Patients randomized to receive 12 weeks of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics ...
In this systematic review and meta-analysis, postdischarge contacts did not significantly affect hospital readmission rates, ...
The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...
In this mixed-methods study, the number of patient-initiated online portal messages moderately decreased with the ...
In this target trial emulation study, denosumab was associated with an increased risk of major adverse cardiovascular events ...
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade 3-4 treatment-related adverse events were reported in 14% in ...
In this cohort study of offspring born to mothers at risk for preterm delivery or diagnosed with an autoimmune or ...
The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback